atoltivimab-maftivimab-odesivimab-ebgn 241.7 MG / 241.7 MG / 241.7 MG per 14.5 ML Injection

RxCUI: 2461536
RxNorm name: atoltivimab-maftivimab-odesivimab-ebgn 241.7 MG / 241.7 MG / 241.7 MG per 14.5 ML Injection
Display name: atoltivimab-maftivimab-odesivimab-ebgn 241.7 MG / 241.7 MG / 241.7 MG per 14.5 ML Injection
Full name: atoltivimab-maftivimab-odesivimab-ebgn 241.7 MG / 241.7 MG / 241.7 MG per 14.5 ML Injection
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:38:46

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761169	Inmazeb	atoltivimab, maftivimab, and odesivimab-ebgn	351(a)	Rx	2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Inmazeb	ATOLTIVIMAB, MAFTIVIMAB, AND ODESIVIMAB-EBGN	Regeneron Pharmaceuticals, Inc.	0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa	2025-12-15	Warnings, Adverse reactions	Exact identifier rxcui: 2461536

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa	atoltivimab-maftivimab-odesivimab-ebgn 241.7 MG / 241.7 MG / 241.7 MG per 14.5 ML Injection	SY	12	These highlights do not include all the information needed to use INMAZEB safely and effectively. See full prescribing information for INMAZEB. INMAZEB ® (atoltivimab, maftivimab, and odesivimab-ebgn) injection, for intravenous use Initial U.S. Approval: 2020	20251215
0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa	14.5 ML atoltivimab-ebgn 16.7 MG/ML / maftivimab-ebgn 16.7 MG/ML / odesivimab-ebgn 16.7 MG/ML Injection	SCD	12	These highlights do not include all the information needed to use INMAZEB safely and effectively. See full prescribing information for INMAZEB. INMAZEB ® (atoltivimab, maftivimab, and odesivimab-ebgn) injection, for intravenous use Initial U.S. Approval: 2020	20251215
0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa	atoltivimab-ebgn 241.7 MG / maftivimab-ebgn 241.7 MG / odesivimab-ebgn 241.7 MG per 14.5 ML Injection	SY	12	These highlights do not include all the information needed to use INMAZEB safely and effectively. See full prescribing information for INMAZEB. INMAZEB ® (atoltivimab, maftivimab, and odesivimab-ebgn) injection, for intravenous use Initial U.S. Approval: 2020	20251215
0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa	atoltivimab-maftivimab-odesivimab-ebgn 241.7 MG / 241.7 MG / 241.7 MG in 14.5 ML Injection	PSN	12	These highlights do not include all the information needed to use INMAZEB safely and effectively. See full prescribing information for INMAZEB. INMAZEB ® (atoltivimab, maftivimab, and odesivimab-ebgn) injection, for intravenous use Initial U.S. Approval: 2020	20251215
0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa	atoltivimab-ebgn 16.67 MG/ML / maftivimab-ebgn 16.67 MG/ML / odesivimab-ebgn 16.67 MG/ML per 14.5 ML Injection	SY	12	These highlights do not include all the information needed to use INMAZEB safely and effectively. See full prescribing information for INMAZEB. INMAZEB ® (atoltivimab, maftivimab, and odesivimab-ebgn) injection, for intravenous use Initial U.S. Approval: 2020	20251215